Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023519 | 0.85 | KDM4E (0.45) | EGLN1XDH | |
| SCHEMBL17472795 | 0.82 | EGLN1 (0.67) | EGLN1XDH | |
| SCHEMBL17472859 | 0.81 | EGLN1 (0.51) | EGLN1XDH | |
| SCHEMBL17472791 | 0.81 | EGLN1 (0.53) | EGLN1XDH | |
| SCHEMBL17472808 | 0.81 | EGLN1 (0.65) | EGLN1XDH | |
| SCHEMBL17472762 | 0.80 | EGLN1 (0.55) | EGLN1XDH | |
| SCHEMBL17472831 | 0.79 | EGLN1 (0.57) | EGLN1XDH | |
| SCHEMBL31023594 | 0.79 | SMN1; SMN2 (0.49) | EGLN1 | |
| SCHEMBL17472792 | 0.79 | EGLN1 (0.53) | EGLN1XDH | |
| SCHEMBL17472869 | 0.77 | EGLN1 (0.69) | EGLN1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | EGLN1 3/4885XDH 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.